Current concepts of treatment in medical oncology: New anticancer drugs

Journal of Cancer Research and Clinical Oncology

Volumn 122, Issue 4, 1996, Pages 189-198

  Unger, Clemens ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Anticancer drug; Drug development; Gene therapy; High dose chemotherapy; Inhibition of angiogenesis; Multidrug resistance

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CLADRIBINE; EDATREXATE; FLUDARABINE; LOMETREXOL; MILTEFOSINE; NAVELBINE; NEW DRUG; PACLITAXEL; PENTOSTATIN; PIRITREXIM; RALTITREXED; SURAMIN; TRIMETREXATE; UNCLASSIFIED DRUG; VINTRIPTOL; VINXALTINE;

ANGIOGENESIS; ANIMAL EXPERIMENT; CANCER CHEMOTHERAPY; CANCER THERAPY; CLINICAL TRIAL; DRUG DEVELOPMENT; HUMAN; HUMAN CELL; MOUSE; MULTIDRUG RESISTANCE; NUDE MOUSE; PRIORITY JOURNAL; REVIEW; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; DNA TOPOISOMERASES, TYPE I; DRUG DESIGN; DRUG RESISTANCE; HUMANS; MICE; NEOPLASMS; SURAMIN;

EID: 0029939285     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01209645     Document Type: Review

References (29)

1. Abigerges D, Chabot GG, Armand JP, Herait P, Gouyette A, Gandia G (1995) Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 13:210-221
2. Barbacid M (1987) RAS genes. Annu Rev Biochem 56:779-827
3. Beutler E (1992) Cladribine (2-chlorodeoxyadenosine). Lancet 340:952-956
4. Budman DR (1992) New vinca alkaloids and related compounds. Semin Oncol 19:639-645
5. Chao CCK, Lee YL, Cheng PW, Ling-Chao S (1991) Enhanced host cell reactivation of damaged plasmid DNA in HeLa cells resistant to cis-diaminedichloroplatinum (II). Cancer Res 51:601-604
6. Cheson BD (1992) New antimetabolites in the treatment of human malignancies. Semin Oncol 19:695-706
7. Christian MC (1992) The current status of new platinum analogs. Semin Oncol 19:720-733
8. Creemerst GJ, Lund B, Verweij T (1994) Cancer Treat Rev 20: 73-96
9. Crown J, Wasserheit C, Hakes T, Feunelly O, Reich L, Moore M, Schneider J, Curttin J, Rubin SC, Reichmann B, Yao TJ, Gilenski T, Gerlati S, Markman M. Norton L (1992) Rapid delivery of multiple high-dose chemotherapy courses with granulocyte colony-stimulating factor and peripheral blood derived hematopoietic progenitor cells. J Natl Cancer Inst 84:1935-1936
10. Dameron KM, Volpert OV, Tainsy MA, Bouck NP (1994) Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 256:1582-1584
11. Eibl H. Unger C (1990) Hexadecylphosphocholine: a new and selective drug. Cancer Treat Rev 17:233-242
12. Eisenberger MA, Fontana JA (1992) Suramin, an active nonhormonal cytotoxic drug for treatment of prostate cancer: compelling reasons for testing in patients with hormone-refractory breast cancer. J Natl Cancer Inst 84:3-5
13. Fleming GF, Schilsky RL (1992) Antifolates: the next generation. Semin Oncol 19:707-719
14. Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1:27-31
15. Gibbs JB (1991) Res C-terminal processing enzymes - new drug targets? Cell 65:1-4
16. Gibbs JB, Pompliano DL, Mosser SD, Rands E, Lingham RB, Singh SB, Scolnick EM, Kohl NE, Oliff A (1993) Selective inhibition of farnesyl-protein transferase blocks ras processing in vivo. J Biol Chem 268:7617-7620
17. Giovanella BC, Stehlin JS, Wall ME (1989) DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 246:1046-1048
18. Hilgard P, Klenner T, Stekar J, Unger C (1993) Alkylphosphocholines: a new class of membrane-active anticancer agents. Cancer Chemother Pharmacol 32:90-95
19. Kim KJ, Li B, Winer J, Armanini M, Gilett N, Phillips MS, Ferrara N (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 362:841-844
20. Kranich AL, Gastl G, Maier-Lenz H, Nagel G (1994) Meeting report: symposium on quality assurance and good clinical practice (GCP) in cancer drug development. J Cancer Res Clin Oncol 120:625-627
21. Lane DP (1992) Cancer p53, guardian of the genome. Nature 358:15-16
22. McGuire WP, Rowinski EK, Rosenhein NB (1989) Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111:273
23. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Look KY, Partridge EE, Davidson M (1995) Taxol and cisplatin (TP) improves outcome in advanced ovarian cancer (AOC) as compared to cytoxan and cisplatin (CP) (abstract). Proc Am Soc Clin Oncol 14:275
24. Miller TP, Grogan TM, Dalton E, Spier CM, Scheper RJ, Salmon SE (1991) P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high dose verapamil. J Clin Oncol 9:17-24
25. Nabholtz JM, Gelmon K, Bontenbal M, et al. (1993) Randomized trial of two doses of taxol in metastatic breast cancer: an interim analysis (abstract). Proc Am Soc Clin Oncol 12:60
26. Omer CA, Kral AM, Diehl RE, Prendergast GC, Powers S, Allen CM, Gibbs JB, Kohl NE (1993) Characterization of recombinant human farnesyl-protein transferase: cloning, expression, farnesyl di-phosphate binding, and functional homology with yeast prenyl-protein transferases. Biochemistry 32:5167-5171
27. Sirotnak FM, Moccio DM, Kellcher LE, Goutsas IJ (1981) Relative frequency and kinetic properties of transport defective phenotypes among methotrexate-resistant L1210 clonal cell lines derived in vivo. Cancer Res 41:4447-4450
28. Sonneveld P, Durie BGM, Lokhorst HM, Marie T, Soebu G, Sucin S, Zittonn R, Cowenberg B, Nooter K (1992) Modulation of multidrug-resislant multiple myeloma by cyclosporin. Lancet 340:255-259
29. Unger C (1989) Alkylphosphocholine und Analoga: Entwicklung einer neuen Substanzgruppe mit antineoplastischer Wirkung. Thieme, Stuttgart